2022 World Conference on Lung Cancer (ePosters)-EP10.01-006. Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients

EP10.01-006. Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients

Back to course

Pdf Summary

Platinum-based combinations are commonly used in chemotherapy for non-small cell lung cancer (NSCLC) and the addition of immunotherapy is considered a state-of-the-art treatment for advanced disease. However, different platinum analogues may have varying levels of toxicity. In order to understand these differences, a study collected data on side effects reported by NSCLC patients.<br /><br />The study used the CareAcross personalized and multilingual support platforms, which allowed patients from 8 different countries to report their diagnoses, treatments, side effects, and other factors through structured questionnaires. By March 2022, a total of 845 patients had reported their treatment regimens and responded to the side effects questionnaire at least once. The focus of the analysis was on treatment combinations chosen at the discretion of clinicians.<br /><br />The results of the study indicate that cisplatin-based combinations are better tolerated than carboplatin-based ones. This real-world data from patient-reported outcomes can guide personalized treatment decisions, taking into account patient status, preferences, comorbidities, and other factors. However, most of the treatment combinations analyzed exhibited similar safety profiles.<br /><br />Specific patterns of differences were identified between combinations that included cisplatin versus carboplatin for the nine most common side effects. Patients receiving cisplatin generally reported fewer side effects compared to those receiving carboplatin in combinations with pembrolizumab or pemetrexed. However, cisplatin was associated with marginally more cough and rash & dry skin in the case of pemetrexed combinations.<br /><br />Overall, these findings suggest that the choice of platinum analogue can impact the frequency and severity of side effects in NSCLC patients. Larger randomized clinical studies can provide more substantial evidence to support these observations. The authors express their gratitude to the cancer patients who contributed to this research.

Asset Subtitle

Christie Lagogianni

Meta Tag

Speaker Christie Lagogianni

Topic Palliative and Supportive Care

Keywords

platinum-based combinations

chemotherapy

non-small cell lung cancer

NSCLC

immunotherapy

toxicity

side effects

CareAcross

personalized support platforms

multilingual support platforms